

7th January 2026

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE Luxembourg
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: Intimation under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Clarification on USFDA inspectional observations in Form 483 on Pharmathen International S.A. ("Pharmathen")

While the Company was in the process of making relevant clarification under Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), it received a communication from Stock Exchanges seeking clarification on the media reports published and displayed across various mainstream media on US Food and Drug Administration (USFDA) inspectional observations in Form 483 on Pharmathen International S.A. (Pharmathen). In this regard, we wish to clarify that Pharmathen is our supply partner, manufacturing Lanreotide Injection for Cipla USA Inc., a wholly owned subsidiary of the Company. As per media reports, based on the Form 483 that became public on 7th January 2026, USFDA conducted an inspection at the manufacturing facility of Pharmathen, located at Rodopi, Greece, from 10th November 2025 to 21st November 2025. Following the inspection, Pharmathen received nine (9) inspectional observations.

Currently, the Company is evaluating the impact of the above event and will keep the Stock Exchanges informed of any update that may have a material impact, in accordance with the applicable regulatory requirements.

Please take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Chirag Hotchandani